BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
BioNTech and DualityBio are mulling what to do next with trastuzumab pamirtecan in certain breast cancer patients after the antibody-drug conjugate delivered a “statistically significant, yet modest” success in a Phase 3 trial. The drugmakers ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.